Middleton & Co. Inc. MA Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Middleton & Co. Inc. MA raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,837 shares of the medical research company’s stock after purchasing an additional 288 shares during the quarter. IQVIA accounts for 1.3% of Middleton & Co. Inc. MA’s holdings, making the stock its 28th largest holding. Middleton & Co. Inc. MA’s holdings in IQVIA were worth $11,336,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Canada Pension Plan Investment Board increased its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the period. Farallon Capital Management LLC lifted its stake in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after acquiring an additional 92,293 shares during the period. Finally, Capital Research Global Investors grew its position in IQVIA by 7.2% in the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after acquiring an additional 143,533 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IQV. Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group boosted their price target on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Robert W. Baird upped their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Finally, Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.27.

IQVIA Price Performance

Shares of IQV opened at $214.63 on Friday. The firm has a fifty day moving average price of $238.13 and a 200 day moving average price of $230.78. The stock has a market cap of $39.11 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.